Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.

Abstract: The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.

Abstract: The specification provides compositions and methods of reducing a risk of a HBV infection in a subject and of treating a subject infected with HBV.

Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as Sa bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.

Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Abstract: The specification provides methods of determining whether a subject suffering from ER+/HER2+ breast cancer is likely to respond to adjuvant and neoadjuvant chemotherapy and methods of treating a subject suffering from ER+/HER2+ breast cancer.

Abstract: Methods and compositions for determining a prognosis for a subject infected with HIV, reducing a risk of an HIV infection, and treating or reducing a risk of developing AIDS are described.

Abstract: Disclosed are novel methods of maintaining articular cartilage health in an atraumatic, non-diseased joint of a mammal, either human or non-human. The methods involve injecting into the joint capsule of the mammal an amount of a lubricin polypeptide to prevent shear-induced chondrocyte apoptosis and to maintain a lubricin-expressing phenotype of chondrocytes.

Abstract: The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.

Abstract: The present specification provides, inter alia, methods of using Wnt and FZD proteins, genes, FZD and Wnt-specific antibodies and probes in diagnosis and treatment of cancer and for screening test compounds for an ability to treat cancer. Also disclosed are compounds useful for treating cancer such as liver cancer.

Abstract: The present specification provides, inter alia, methods of using Wnt and FZD proteins and genes, and Wnt- and FZD-specific antibodies and probes in diagnosis and treatment of cancer and for screening test compounds for an ability to treat cancer. Also disclosed are compounds useful for treating cancer such as liver cancer.

Abstract: A system for determining an indication of animal joint mobility includes a mounting apparatus configured to hold a first condyle of the joint stationary in a position such that a second condyle of the joint can pivot about the joint, a pendulum configured to be coupled to the second condyle and configured such that a portion of a weight of the pendulum is disposed below a pivot axis of the joint such that the pendulum and second condyle can oscillate about the pivot axis, an angular displacement indicator associated with the pendulum, an angular displacement recorder configured to store indicia of the angular displacement, as indicated by the angular displacement indicator; of the pendulum over time, and a processor coupled to the angular displacement recorder and configured to use the angular displacement indicia to determine a first value associated with momentum decay of oscillations of the pendulum and to use the at least one value to determine a second value associated with a coefficient of friction of t

Abstract: The invention features a lubricating polyeptide and methods of lubricating joints or other tissues by administering the polypeptide systemically or directly to tissues.

Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

Abstract: A method for diagnosing a tumor in the central nervous system of a mammal is carried out by contacting a bodily fluid from the mammal with a ligand which binds to inter-alpha trypsin inhibitor.

Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

Abstract: The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.